Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Kauffels, Anne; Kitzmüller, Marie; Gruber, A.; Nowack, Hannah; Bohnenberger, Hanibal; Spitzner, Melanie; Kuthning, Anja; Sprenger, Thilo; Czejka, Martin; Ghadimi, Michael; Sperling, Jens

doi:10.1007/s10585-019-09954-5

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conjunction with this, combining locoregional therapy such as hepatic arterial infusion or transarterial chemoembolization with nanotechnology and the use of intratumor depots/implants for sustained release may overcome the limitations of the tumor biology. In a rat model of CRC liver metastases, Kauffels et al (2019) were able to show that delivery of drug loaded into embolization particles (Irinotecan with EmboCept S) using hepatic arterial infusion led to significantly higher concentrations within the tumor when compared with systemic administration. Clearly, the application and toxicity of such delivery strategies requires further investigation.…”

Section: The Tumor Microenvironmentmentioning

confidence: 99%

Critical considerations for targeting colorectal liver metastases with nanotechnology

Arshad

Sutton

Treacher³

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Colorectal cancer remains a significant cause of morbidity and mortality worldwide. Half of all patients develop liver metastases, presenting unique challenges for their treatment. The shortcomings of conventional chemotherapy has encouraged the use of nanomedicines; the application of nanotechnology in the diagnosis and treatment of disease. In spite of technological improvements in nanotechnology, the complexity of biological systems hinders the prospect of nanomedicines being applied in cancer therapy at the present time. This review highlights current biological barriers and discusses aspects of tumor biology together with the physicochemical features of the nanocarrier, that need to be considered in order to develop effective nanotherapeutics for colorectal cancer patients with liver metastases. It becomes clear that incorporating an interdisciplinary approach when developing nanomedicines should assure appropriate disease‐driven design and that this will form a critical step in improving their clinical translation. This article is characterized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: The Tumor Microenvironmentmentioning

confidence: 99%

Critical considerations for targeting colorectal liver metastases with nanotechnology

Arshad

Sutton

Treacher³

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Moreover, positron emission tomography/computed tomography (PET-CT) studies have shown a significant association between the area of embolizate retention in CRC metastases and the response to treatment [ 7 ]. Temporary stasis produced during Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) procedures of liver vessels, by preventing rapid leaking of irinotecan and its metabolite SN-38 from the tumor, may affect treatment efficacy [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis

et al. 2021

View full text Add to dashboard Cite

Chemoembolization with irinotecan-loaded microspheres has proven effective in the treatment of unresectable liver metastases in the course of colorectal cancer (CRC). Most researchers recommend slowly administering the embolizate at the level of the lobar arteries, without obtaining visible stasis. However, there are reports of a relationship between postoperative embolizate retention in metastatic lesions and the response to treatment. To retain residual embolizate throughout the entire neoplastic lesion requires a temporary flow stop (stasis) within all supply vessels, which may cause temporary stasis in subsegmental or even segmental vessels. Objective: To assess the risk of complications and post-embolization syndrome severity following chemoembolization of CRC metastatic liver lesions with microspheres loaded with Irinotecan, with regard to hepatic-artery branch level of temporary stasis. Patients and methods: The study included 52 patients (29 female, 23 male) with liver metastases from CRC, who underwent 202 chemoembolization treatments (mean: 3.88 per patient) with microspheres loaded with 100 mg irinotecan. Postembolization syndrome (PES) severity and complication occurrence were assessed with regard to the hepatic-artery branch level of temporary stasis. Adverse events were assessed according to Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events. Results: Median survival from the start of chemoembolization was 13 months. From 202 chemoembolization sessions, 15 (7.4%) significant complications were found. The study found a significant relationship between the branch level of temporary stasis and the presence of complications (p < 0.001), with the highest number of complications observed with temporary stasis in segmental vessels. PES was diagnosed after 103 (51%) chemoembolization treatments. A significant association was found between PES severity and the branch level of temporary stasis (p < 0.001). Conclusions: The branch level of temporary stasis affected the severity of post-embolization syndrome. A significant association was found between the branch level of temporary stasis obtained in chemoembolization procedures and the presence of complications. The apparent lack of change in numbers of complications when stasis was applied at tumor supply vessels or subsegmental arteries may indicate the safe use of temporary stasis in some cases where colorectal cancer metastases are treated. Further research is needed to determine the most effective chemoembolization technique.

show abstract

Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model

Kauffels

Nowack

Bohnenberger

et al. 2023

Clin Exp Metastasis

View full text Add to dashboard Cite

Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Cited by 5 publications

References 36 publications

Critical considerations for targeting colorectal liver metastases with nanotechnology

Critical considerations for targeting colorectal liver metastases with nanotechnology

Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis

Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model

Contact Info

Product

Resources

About